Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06573281 · ClinicalTrials.gov registry record · Phase 1

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

A Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
213
Enrollment target
9
Study locations

NCT06573281 is a Phase 1 study of Respiratory Syncytial Virus Infections that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 213 participants, below the 1,081-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06573281, a Phase 1 study of Respiratory Syncytial Virus Infections, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
213 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.

Conditions Studied

Respiratory Syncytial Virus Infections

Interventions

  • BIOLOGICAL Investigational RSV vaccine 1
  • BIOLOGICAL Investigational RSV vaccine 2
  • BIOLOGICAL Investigational RSV vaccine 3
  • BIOLOGICAL Investigational RSV vaccine 4
  • BIOLOGICAL Investigational RSV vaccine 5

Study Locations (9)

Other

  • GSK Investigational Site - Madrid
  • GSK Investigational Site - Madrid
  • GSK Investigational Site - Madrid

California

  • GSK Investigational Site - Rolling Hills Estates

Georgia

  • GSK Investigational Site - Atlanta

Kansas

  • GSK Investigational Site - Lenexa

Nebraska

  • GSK Investigational Site - Omaha

New York

  • GSK Investigational Site - Rochester

Victoria

  • GSK Investigational Site - Camberwell

Trial Details

FieldValue
Enrollment Target 213 participants
Start Date 2024-09-30
Est. Completion 2026-04-13
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06573281

The ClinicalTrials.gov registry entry for NCT06573281 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,081-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (80% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 5 interventions - of which Investigational RSV vaccine 1 is the first listed.

NCT06573281 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06573281 about?

NCT06573281 is a clinical study titled "A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years". The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.

What is the current status of trial NCT06573281?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2024-09-30. Estimated completion is 2026-04-13.

What conditions does trial NCT06573281 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.

What interventions are being tested in trial NCT06573281?

The interventions under investigation include: Investigational RSV vaccine 1 (BIOLOGICAL), Investigational RSV vaccine 2 (BIOLOGICAL), Investigational RSV vaccine 3 (BIOLOGICAL), Investigational RSV vaccine 4 (BIOLOGICAL), Investigational RSV vaccine 5 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06573281?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06573281 being conducted?

This trial has 9 study locations across California, Georgia, Kansas, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Respiratory Syncytial Virus Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.